Table 2 lists the main clinical trials of SGLT2 inhibitors assessing cardiovascular and renal outcomes, with some of them conducted in patients also having diabetic kidney disease (DKD) and heart failure with reduced ejection fraction (HFrEF). This evidence concerns the gene SLC5A2 and heart failure.